Kraj: Irlandia
Język: angielski
Źródło: HPRA (Health Products Regulatory Authority)
RESPIRATORY SYNCYTIAL VIRUS INACTIVATED
Novartis Animal Vaccines Ltd
QI02AA
Suspension for Injection
Immunological - Inactivated vaccine
Bovine
2001-02-16
IRISH MEDICINES BOARD ACT 1995 MEDICINAL PRODUCTS(LICENSING AND SALE)REGULATIONS, 1998 (S.I. NO.142 OF 1998) 10974/014/001 Case No: 7002616 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to NOVARTIS ANIMAL VACCINES LTD 4 WARNER DRIVE, SPRINGWOOD INDUSTRIAL ESTATE, RAYNE ROAD, BRAINTREE, ESSEX CM7 2YW, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product TORVAC The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 20/12/2006 until . Signed on behalf of the Irish Medicines Board ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 21/12/2006_ _CRN 7002616_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT TORVAC 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 3 PHARMACEUTICAL FORM Suspension for injection. Torvac is presented as a transparent aqueous liquid containing a cell suspension. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES The product is indicated for use in cattle, particularly young calves from 10 days of age. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Torvac is indicated for the active immunisation of calves thereby delaying the onset and reducing the duration of viral shedding due to Bovine Respiratory Syncytial Virus. Calves have been shown to be protected from 21 days after second va Przeczytaj cały dokument